NIH VideoCast - TB: It Takes More than a Village to Raise a Remedy

Skip Navigation

TB: It Takes More than a Village to Raise a Remedy

Loading... Loading video...

389 Views

Air date:	Friday, November 22, 2013, 10:00:00 AM Time displayed is Eastern Time, Washington DC Local
Views:	Total views: 389 (176 Live, 213 On-demand)
Category:	Philip S. Chen - Innovation & Technology Transfer
Runtime:	01:14:51
Closed captioning:	Check box to display CC outside of the video Note: You can drag the captioning window around and resize it
Description:	8th Annual Philip S. Chen, Jr., Ph.D. Distinguished Lecture on Innovation and Technology Transfer Dr. Clifton E. Barry received his Ph.D. degree in organic and bioorganic chemistry in 1989 from Cornell University, and then was a postdoctoral fellow in the department of chemistry at the Johns Hopkins University. In 1991, he joined the NIH intramural research program as an investigator at the Rocky Mountain Laboratories, studying DNA-protein interactions during chlamydial development. In 1993 he established the Mycobacterial Research Unit that initially studied mycolic acid biosynthesis in Mycobacterium tuberculosis. In 1998, he was tenured as a Senior Investigator of the Tuberculosis Research Section (TRS) and relocated his laboratory to the Bethesda area. The TRS is a multidisciplinary group of research scientists comprised of biologists, chemists and clinical researchers who share a common interest in TB. TRS projects focus on understanding the scientific issues that facilitate the development of drugs that will make a genuine difference in the outcome for TB patients globally. TRS scientists are highly interactive worldwide in this endeavor and as a result of our outstanding collaborations TRS is the most widely cited TB research group in the world. In addition to current TRS laboratories in Bethesda TRS works closely with the International Tuberculosis Research Center located in Masan, South Korea; with Chinese colleagues at the Henan Provincial Chest Hospital in Zhengzhou, China; and with colleagues at Stellenbosch University and the University of Cape Town in South Africa. Dr. Carol A. Nacy is founder and Chief Executive Officer of Sequella, Inc., privately-held pharmaceutical company founded in 1997 that develops new and more effective treatments for life-threatening infectious diseases. Sequella has a novel antibiotic in Phase 2 efficacy studies in Africa for drug-sensitive tuberculosis (TB), a registration trial in Russia for drug-resistant TB, and Phase 2 efficacy studies in Texas for Helicobacter pylori

NLM Title:	TB : it takes more than a village to raise a remedy / Clifton E. Barry and Carol A. Nacy.
Author:	Barry, Clifton E. National Institutes of Health (U.S.),
Publisher:
Abstract:	(CIT): 8th Annual Philip S. Chen, Jr., Ph.D. Distinguished Lecture on Innovation and Technology Transfer Dr. Clifton E. Barry received his Ph.D. degree in organic and bioorganic chemistry in 1989 from Cornell University, and then was a postdoctoral fellow in the department of chemistry at the Johns Hopkins University. In 1991, he joined the NIH intramural research program as an investigator at the Rocky Mountain Laboratories, studying DNA-protein interactions during chlamydial development. In 1993 he established the Mycobacterial Research Unit that initially studied mycolic acid biosynthesis in Mycobacterium tuberculosis. In 1998, he was tenured as a Senior Investigator of the Tuberculosis Research Section (TRS) and relocated his laboratory to the Bethesda area. The TRS is a multidisciplinary group of research scientists comprised of biologists, chemists and clinical researchers who share a common interest in TB. TRS projects focus on understanding the scientific issues that facilitate the development of drugs that will make a genuine difference in the outcome for TB patients globally. TRS scientists are highly interactive worldwide in this endeavor and as a result of our outstanding collaborations TRS is the most widely cited TB research group in the world. In addition to current TRS laboratories in Bethesda TRS works closely with the International Tuberculosis Research Center located in Masan, South Korea; with Chinese colleagues at the Henan Provincial Chest Hospital in Zhengzhou, China; and with colleagues at Stellenbosch University and the University of Cape Town in South Africa. Dr. Carol A. Nacy is founder and Chief Executive Officer of Sequella, Inc., privately-held pharmaceutical company founded in 1997 that develops new and more effective treatments for life-threatening infectious diseases. Sequella has a novel antibiotic in Phase 2 efficacy studies in Africa for drug-sensitive tuberculosis (TB), a registration trial in Russia for drug-resistant TB, and Phase 2 efficacy studies in Texas for Helicobacter pylori.
Subjects:	International Cooperation Tuberculosis, Pulmonary--drug therapy
Publication Types:	Lecture Webcast

NLM Classification:	WF 200
NLM ID:	101622769
CIT Live ID:	13355
Permanent link:	https://videocast.nih.gov/watch=13355

Related Videos...